Drug Trial Radar · NCT07202663
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 5, 2025
Primary completion
Mar 18, 2026
Study completion Mar 18, 2026
Sponsor
- Lead sponsor
- Basking Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent. In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms. In the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.
Conditions
- Pharmacodynamics
- Pharmacokinetics
- Healthy Volunteers
Interventions
BB-025Drug
Reversal agent for BB-031
BB-031Drug
RNA aptamer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as assessed by adverse events (AEs)Time frame: From dosing of study drug to final visit (Day 28)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scintia Clinical Research Ltd
Randwick, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.